NEW YORK, NY: Report Cites the Potential of Immunomodulating Monoclonal Antibodies to Address Multiple Indications in Cancer and Chronic Inflammation Lead Programs Out-Licensed to Bristol-Myers Squibb and Novo Nord ...
WINNIPEG, MANITOBA: Highlights: - Wound gel reduced over 95% of biofilm-embedded bacteria versus approximately 50% reduction by industry leading product - Superior performance is due to synergy between DispersinB(R) and ...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.